These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 37191192)

  • 21. Conditional Alpl Ablation Phenocopies Dental Defects of Hypophosphatasia.
    Foster BL; Kuss P; Yadav MC; Kolli TN; Narisawa S; Lukashova L; Cory E; Sah RL; Somerman MJ; Millán JL
    J Dent Res; 2017 Jan; 96(1):81-91. PubMed ID: 27582029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcimimetics Alter Periosteal and Perilacunar Bone Matrix Composition and Material Properties in Early Chronic Kidney Disease.
    Damrath JG; Moe SM; Wallace JM
    J Bone Miner Res; 2022 Jul; 37(7):1297-1306. PubMed ID: 35593150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
    Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
    Hsu CY; Chen LR; Chen KH
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Active Vitamin D or FGF23 Antibody on
    Lira Dos Santos EJ; Chavez MB; Tan MH; Mohamed FF; Kolli TN; Foster BL; Liu ES
    J Dent Res; 2021 Dec; 100(13):1482-1491. PubMed ID: 33906518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
    Ota M; Takahata M; Shimizu T; Kanehira Y; Kimura-Suda H; Kameda Y; Hamano H; Hiratsuka S; Sato D; Iwasaki N
    Osteoporos Int; 2017 Apr; 28(4):1481-1490. PubMed ID: 27933339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of GSK-3β increases trabecular bone volume but not cortical bone volume in adenine-induced uremic mice with severe hyperparathyroidism.
    Tatsumoto N; Arioka M; Yamada S; Takahashi-Yanaga F; Tokumoto M; Tsuruya K; Kitazono T; Sasaguri T
    Physiol Rep; 2016 Nov; 4(21):. PubMed ID: 27803315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model.
    Sato H; Goto M; Nishimura G; Morimoto N; Tokushima H; Horii Y; Takahashi N
    Bone; 2023 Feb; 167():116613. PubMed ID: 36395959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Importance of Phosphate Control in Chronic Kidney Disease.
    Tsuchiya K; Akihisa T
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of sphingolipid metabolism signaling in a novel mouse model of renal osteodystrophy based on transcriptomic approach.
    Wang Y; Di Y; Li Y; Lu J; Ji B; Zhang Y; Chen Z; Chen S; Liu B; Tang R
    Chin Med J (Engl); 2024 Aug; ():. PubMed ID: 39149978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure.
    Nikolov IG; Joki N; Nguyen-Khoa T; Ivanovski O; Phan O; Lacour B; Drüeke TB; Massy ZA; Dos Reis LM; Jorgetti V; Lafage-Proust MH
    Bone; 2010 Jul; 47(1):156-63. PubMed ID: 20406703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of PHOSPHO1 in Periodontal Development and Function.
    Zweifler LE; Ao M; Yadav M; Kuss P; Narisawa S; Kolli TN; Wimer HF; Farquharson C; Somerman MJ; Millán JL; Foster BL
    J Dent Res; 2016 Jul; 95(7):742-51. PubMed ID: 27016531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exogenous BMP7 administration attenuated vascular calcification and improved bone disorders in chronic uremic rats.
    Lee CT; Kuo WH; Tain YL; Wang Y; Lee WC
    Biochem Biophys Res Commun; 2022 Sep; 621():8-13. PubMed ID: 35809346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated network pharmacology, transcriptomics, and metabolomics analysis to reveal the mechanism of salt Eucommiae cortex in the treatment of chronic kidney disease mineral bone disorders via the PPARG/AMPK signaling pathway.
    Shen J; Liu Y; Wang Q; Chen H; Hu Y; Guo X; Liu X; Li Y
    J Ethnopharmacol; 2023 Oct; 314():116590. PubMed ID: 37207881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Periodontal Defects in the A116T Knock-in Murine Model of Odontohypophosphatasia.
    Foster BL; Sheen CR; Hatch NE; Liu J; Cory E; Narisawa S; Kiffer-Moreira T; Sah RL; Whyte MP; Somerman MJ; Millán JL
    J Dent Res; 2015 May; 94(5):706-14. PubMed ID: 25716980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
    Pazianas M; Miller PD
    J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
    de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
    Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
    Chen NX; Srinivasan S; O'Neill K; Nickolas TL; Wallace JM; Allen MR; Metzger CE; Creecy A; Avin KG; Moe SM
    J Bone Miner Res; 2020 Mar; 35(3):608-617. PubMed ID: 31743501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Damrath JG; Chen NX; Metzger CE; Srinivasan S; O'Neill K; Biruete A; Avin KG; Wallace JM; Allen MR; Moe SM
    JBMR Plus; 2022 Mar; 6(3):e10600. PubMed ID: 35309859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.